Nkarta, Inc. · NASDAQ:NKTX
Nkarta — Investor Presentation (January 2024)
24 slides from Nkarta's investor presentation, Jan 8, 2024
Slide 1: Engineering Natural Killer Cells for next generation treatment of cancer and autoimmune diseases
JANUARY 2024 ENGINEERING Natural Killer Cells for next generation treatment of cancer and autoimmune diseases ON DEMAND Exhibit 99.1
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward‐looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, regarding future events and the future results of the company that are based on current expectations, estimates, forecasts, and projections ab
Slide 3: Delivering the future of cell therapy by harnessing the killing ability of NK cells
Delivering the future of cell therapy by harnessing the killing ability of natural killer (NK) cells CARs engineered for optimal target cell killing CAR NK Cell CAR membrane bound IL-15 Candidates engineered with a targeting CAR and membrane bound IL-15 Fully allogeneic from healthy, pre-screened do
Slide 4: Pipeline with transformational potential
NKX101 (NKG2D) Solid Tumors Gated on proof of concept in r/r AML NKX070 (CD70) Heme & Solid Tumors Collaboration NK + T (Undisclosed) Undisclosed Collaboration Pipeline with transformational potential Program (Target) Indication Research IND-Enabling Clinical Status NKX019 (CD19) Lupus Nephritis (SL
Slide 5: NKX019 in Autoimmune Disease
NKX019 in Autoimmune Disease
Slide 6: Effectiveness of current therapies is inadequate
Effectiveness of current therapies is inadequate Often consists of lifelong immune suppression B-cell directed agents have limited activity CD19-directed cell therapy has challenged the treatment paradigm for autoimmune diseases Drug-free remissions after a single treatment in academic trials2 Autoi
Slide 7: Transient CAR T cell persistence differing from CAR T in oncology
Transient CAR T cell persistence, (peaking ~10 days) differing from CAR T in oncology In oncology, long-term CAR T cell engraftment and B cell aplasia are common Less antigen burden may explain difference in persistence and exposure CD19-directed cell therapy leads to long-term responses despite sho
Slide 8: Patient samples show effective elimination of CD19+ cells by NKX019
Patient samples from ongoing NHL trial show effective elimination of CD19+ cells from circulation by NKX019 Normal and malignant cells cleared with a single cycle Deep suppression achieved by day 30 NKX019 targets and kills cells from patients across indications E:T Ratio NT control NKX019 n=3 patie
Slide 9: CD19 CAR NK cells may be ideally suited for autoimmune disease
NK cells reach peak activity at infusion for rapid target exposure Allows maximal immediate effect without in vivo expansion or permanent engraftment T cells require expansion, which delays effects and requires lymphodepletion (LD) Opportunity to reduce chemotherapy exposure via disease-tailored LD
Slide 10: NKX019 CAR NK for autoimmune diseases: phase 1 study
NKX019 CAR NK for autoimmune diseases: A multicenter, open-label, phase 1 study NKX019 1B or 1.5B CAR-NK cells/dose Lymphodepletion Cyclophosphamide 1000 mg/m2 once Day -3 Day 0 Day 7 Day 14 First patient dosing expected 1H 2024 CAR: chimeric antigen receptor Endpoints: 3 doses per cycle Opportunity
Slide 11: NKX019 and NKX101 in oncology
NKX019 and NKX101 in oncology
Slide 12: NKX019 CD19 CAR NK in r/r non-Hodgkin lymphoma
NKX019 CD19 CAR NK in r/r non-Hodgkin lymphoma
Slide 13: CAR T-cell therapy is not broadly accessible
CAR T-cell therapy is not broadly accessible Only 20-30% of patients with LBCL who could benefit from CAR T receive it Patients often need to change providers and receive bridging chemotherapy Potential toxicity requires proximity to a specialized inpatient treatment center Over 25% of patients requ
Slide 14: NKX019 for B-cell malignancies: phase 1 study in r/r NHL
NKX019 for B-cell malignancies: A multicenter, open-label, phase 1 study in r/r NHL NKX019 3 doses per 28-day cycle Lymphodepletion Cyclophosphamide Fludarabine Efficacy assessment Dose 1 Dose 2 Dose 3 Dickinson, et al. Oral presentation at EHA 2023, program section s347. 4 of 4 CR in retreatment of
Slide 15: NKX019 Amendment: Compressed Dosing
NKX019 Amendment: Compressed Dosing Dose compression cohort enrolling patients with large B-cell lymphoma (LBCL), targeting patients who have received prior CD19 CAR-T cell therapy New compressed dosing schedule to intensify exposure to NKX019 in the first week after LD Previous cohorts received NKX
Slide 16: NKX019 has superior target cell killing compared to CD19 CAR T cells
NKX019 has superior target cell killing compared to CD19 CAR T cells, even with low levels of CD19 expression NKX019 Low CD19 Expressing Cells High CD19 Expressing Cells NKX019 CD19 CAR-T CD19 CAR-T Effector : Target Effector : Target Nalm6 cells engineered to express varying levels of CD19 were obt
Slide 17: NKX101 NKG2D CAR NK in r/r acute myeloid leukemia
NKX101 NKG2D CAR NK in r/r acute myeloid leukemia
Slide 18: AML is a rapidly progressing leukemia with a poor prognosis
Heterogenous group of blood cancers treated with risk-adapted chemotherapy Most patients will ultimately die from relapse or complications from therapy Allogeneic HCT is best chance of long-term cure Limited to patients who are fit Pre-HCT CR improves outcomes Outcomes for patients who relapse or ha
Slide 19: NKX101 for relapsed/refractory AML following disease-tailored LD
Fludarabine/Ara-C with anthracycline (e.g. FLAG-Ida) is a frequent salvage regimen for r/r AML with true CR rate of ~10% and cCR rate of ~20% as a comparator arm Anthracyclines (idarubicin, mitoxantrone, etc.) add toxicity and limit addressable population Ara-C (cytarabine) is a DNA damaging agent w
Slide 20: ASH 2023: Updated follow-up of patients with r/r AML
4 of 6 patients achieved CR/CRi High-risk features such as prior HCT, TP53 mutation and high blast burden 3 of 4 remained in CR/CRi at 4 months ASH 2023: Updated follow-up of patients with r/r AML Sauter, et al. ASH 2023 AML, acute myeloid leukemia; CAR, chimeric antigen receptor; CR, complete respo
Slide 21: NKX101 exposure consistent with previously published data
NKX101 dosed on days 0, 7, and 14 Exposure consistent with previously published data using haploidentical NK cells1 No need for exogenous IL-2 or other cytokine support Disease-tailored lymphodepletion does not compromise PK Fludarabine/Cyclophosphamide Fludarabine/Ara-C Median NK101 copies/ug DNA M
Slide 22: Ligands are upregulated with stress, including chemotherapy
Ligands are upregulated with stress, including chemotherapy NKG2D CAR binds to 8 known ligands Mediates natural target cell elimination Pre-treatment of AML cells increases sensitivity to NK killing in vivo Dose dependent effect May increase opportunity for CAR-mediated killing Ara-C upregulates NKG
Slide 23: Summary
Summary nkarta
Slide 24: Autoimmune expansion, 2024 updates, cash runway
Autoimmune expansion | 2024 updates | Cash runway Anticipated 2024 clinical milestones 1H 2024 NKX019 in lupus nephritis - Dose first patient and program update 1H 2024 NKX101 in AML - Clinical data from 12 to 20 new patients in flu/Ara-C cohort Mid 2024 NKX019 in NHL - Clinical data from dose compr